HCPCS Level II Code Lookup
Look up official HCPCS Level II codes for products, supplies, drugs, equipment and services, or browse by letter family below.
- Current release
- October 2026 effective October 1, 2026
- Active codes
- 7,448 active codes
- Maintainer
- Maintained by CMS
Browse by Letter Family
8,769 codes, grouped by their leading letter.
P
- P2029 Congo red, blood
- P2031 Hair analysis (excluding arsenic)
- P2033 Thymol turbidity, blood
- P2038 Mucoprotein, blood (seromucoid) (medical necessity procedure)
- P3000 Screening papanicolaou smear, cervical or vaginal, up to three smears, by technician under physician supervision
- P3001 Screening papanicolaou smear, cervical or vaginal, up to three smears, requiring interpretation by physician
- P7001 Culture, bacterial, urine; quantitative, sensitivity study
- P9010 Blood (whole), for transfusion, per unit
- P9011 Blood, split unit
- P9012 Cryoprecipitate, each unit
- P9016 Red blood cells, leukocytes reduced, each unit
- P9017 Fresh frozen plasma (single donor), frozen within 8 hours of collection, each unit
- P9019 Platelets, each unit
- P9020 Platelet rich plasma, each unit
- P9021 Red blood cells, each unit
- P9022 Red blood cells, washed, each unit
- P9023 Plasma, pooled multiple donor, solvent/detergent treated, frozen, each unit
- P9025 Plasma, cryoprecipitate reduced, pathogen reduced, each unit
- P9026 Cryoprecipitated fibrinogen complex, pathogen reduced, each unit
- P9027 Red blood cells, leukocytes reduced, oxygen/ carbon dioxide reduced, each unit
- P9031 Platelets, leukocytes reduced, each unit
- P9032 Platelets, irradiated, each unit
- P9033 Platelets, leukocytes reduced, irradiated, each unit
- P9034 Platelets, pheresis, each unit
- P9035 Platelets, pheresis, leukocytes reduced, each unit
- P9036 Platelets, pheresis, irradiated, each unit
- P9037 Platelets, pheresis, leukocytes reduced, irradiated, each unit
- P9038 Red blood cells, irradiated, each unit
- P9039 Red blood cells, deglycerolized, each unit
- P9040 Red blood cells, leukocytes reduced, irradiated, each unit
- P9041 Infusion, albumin (human), 5%, 50 ml
- P9043 Infusion, plasma protein fraction (human), 5%, 50 ml
- P9044 Plasma, cryoprecipitate reduced, each unit
- P9045 Infusion, albumin (human), 5%, 250 ml
- P9046 Infusion, albumin (human), 25%, 20 ml
- P9047 Infusion, albumin (human), 25%, 50 ml
- P9048 Infusion, plasma protein fraction (human), 5%, 250 ml
- P9050 Granulocytes, pheresis, each unit
- P9051 Whole blood or red blood cells, leukocytes reduced, cmv-negative, each unit
- P9052 Platelets, hla-matched leukocytes reduced, apheresis/pheresis, each unit
- P9053 Platelets, pheresis, leukocytes reduced, cmv-negative, irradiated, each unit
- P9054 Whole blood or red blood cells, leukocytes reduced, frozen, deglycerol, washed, each unit
- P9055 Platelets, leukocytes reduced, cmv-negative, apheresis/pheresis, each unit
- P9056 Whole blood, leukocytes reduced, irradiated, each unit
- P9057 Red blood cells, frozen/deglycerolized/washed, leukocytes reduced, irradiated, each unit
- P9058 Red blood cells, leukocytes reduced, cmv-negative, irradiated, each unit
- P9059 Fresh frozen plasma between 8-24 hours of collection, each unit
- P9060 Fresh frozen plasma, donor retested, each unit
- P9070 Plasma, pooled multiple donor, pathogen reduced, frozen, each unit
- P9071 Plasma (single donor), pathogen reduced, frozen, each unit
- P9072 Platelets, pheresis, pathogen reduced or rapid bacterial tested, each unit Historical
- P9073 Platelets, pheresis, pathogen-reduced, each unit
- P9099 Blood component or product not otherwise classified
- P9100 Pathogen(s) test for platelets
- P9603 Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled
- P9604 Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge
- P9612 Catheterization for collection of specimen, single patient, all places of service
- P9615 Catheterization for collection of specimen(s) (multiple patients)
Q
- Q0035 Cardiokymography
- Q0081 Infusion therapy, using other than chemotherapeutic drugs, per visit
- Q0083 Chemotherapy administration by other than infusion technique only (e.g., subcutaneous, intramuscular, push), per visit
- Q0084 Chemotherapy administration by infusion technique only, per visit
- Q0085 Chemotherapy administration by both infusion technique and other technique(s) (e.g., subcutaneous, intramuscular, push), per visit
- Q0091 Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory
- Q0092 Set-up portable x-ray equipment
- Q0111 Wet mounts, including preparations of vaginal, cervical or skin specimens
- Q0112 All potassium hydroxide (koh) preparations
- Q0113 Pinworm examinations
- Q0114 Fern test
- Q0115 Post-coital direct, qualitative examinations of vaginal or cervical mucous
- Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
- Q0139 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis)
- Q0144 Azithromycin dihydrate, oral, capsules/powder, 1 gram
- Q0155 Dronabinol (syndros), 0.1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
- Q0161 Chlorpromazine hydrochloride, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
- Q0162 Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
- Q0163 Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen
- Q0164 Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
- Q0166 Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen
- Q0167 Dronabinol, 2.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
- Q0169 Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
- Q0173 Trimethobenzamide hydrochloride, 250 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
- Q0174 Thiethylperazine maleate, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen Historical
- Q0175 Perphenazine, 4 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
- Q0177 Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
- Q0180 Dolasetron mesylate, 100 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen
- Q0181 Unspecified oral dosage form, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for a iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
- Q0220 Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg Historical
- Q0221 Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg Historical
- Q0222 Injection, bebtelovimab, 175 mg Historical
- Q0224 Injection, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, and who either have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments, and are unlikely to mount an adequate immune response to covid-19 vaccination, 4500 mg
- Q0234 Injection, tocilizumab-bavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, 1 mg
- Q0235 Injection, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, not otherwise classified, 1 mg
- Q0237 Injection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
- Q0238 Injection, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
- Q0239 Injection, bamlanivimab-xxxx, 700 mg Historical
- Q0240 Injection, casirivimab and imdevimab, 600 mg Historical
- Q0243 Injection, casirivimab and imdevimab, 2400 mg Historical
- Q0244 Injection, casirivimab and imdevimab, 1200 mg Historical
- Q0245 Injection, bamlanivimab and etesevimab, 2100 mg Historical